Stock listing
NASDAQ:NRSN NeuroSense Therapeutics Ltd. Stock
Home listing (NASDAQ) of NeuroSense Therapeutics Ltd.
Follow NeuroSense Therapeutics Ltd. into a list and get an email when it puts out news.
Share price · NASDAQ:NRSN
$1.28 USD -0.09 (-6.6%)
Close on Nov 20, 2026
- Day range
- $1.27 – $1.34 USDNov 20, 2026
- Volume
- 9,960 sharesNov 20, 2026
- Market cap
- $2.43M USDAt the close on Nov 20, 2026 · price × 1.90M shares outstanding
- 52-week range
- $1.10 – $24.80 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $75,165 USDMedian day 13,848 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NRSN · Home | $1.28 USD | -0.09 (-6.6%) | 9,960 | $1.32 | $1.343 | $1.27 | $1.37 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NRSN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.28 | -0.09 | -6.6% | $1.32 | $1.343 | $1.27 | 9,960 | |
| $1.37 | -0.14 | -9.3% | $1.58 | $1.58 | $1.33 | 14,600 | |
| $1.51 | -0.055 | -3.5% | $1.54 | $1.61 | $1.495 | 11,971 | |
| $1.565 | -0.125 | -7.4% | $1.69 | $1.69 | $1.52 | 9,354 | |
| $1.69 | -0.07 | -4.0% | $1.72 | $1.78 | $1.59 | 18,304 | |
| $1.76 | -0.02 | -1.1% | $1.816 | $1.83 | $1.73 | 29,640 | |
| $1.78 | -0.20 | -10.1% | $1.98 | $2.17 | $1.70 | 51,943 | |
| $1.98 | +0.12 | +6.5% | $1.85 | $2.01 | $1.60 | 48,951 | |
| $1.86 | +0.18 | +10.7% | $1.74 | $1.87 | $1.60 | 38,512 | |
| $1.68 | +0.285 | +20.4% | $1.47 | $1.68 | $1.30 | 17,313 | |
| $1.395 | -0.025 | -1.8% | $1.50 | $1.59 | $1.34 | 51,320 | |
| $1.42 | +0.14 | +10.9% | $1.28 | $1.45 | $1.28 | 24,529 | |
| $1.28 | -0.15 | -10.5% | $1.40 | $1.46 | $1.20 | 25,037 | |
| $1.43 | -0.56 | -28.1% | $2.02 | $2.04 | $1.10 | 407,490 | |
| $1.99 | -0.14 | -6.6% | $2.20 | $2.22 | $1.99 | 20,177 | |
| $2.13 | -0.23 | -9.7% | $2.302 | $2.32 | $2.09 | 20,577 | |
| $2.36 | -0.01 | -0.4% | $2.33 | $2.37 | $2.20 | 17,301 | |
| $2.37 | +0.04 | +1.7% | $2.30 | $2.60 | $2.28 | 22,274 | |
| $2.33 | -0.13 | -5.3% | $2.466 | $2.75 | $2.31 | 29,709 | |
| $2.46 | +0.02 | +0.8% | $2.49 | $2.55 | $2.40 | 11,153 | |
| $2.44 | -0.12 | -4.7% | $2.55 | $2.57 | $2.15 | 18,597 | |
| $2.56 | +0.17 | +7.1% | $2.46 | $2.70 | $2.41 | 11,270 | |
| $2.39 | -0.275 | -10.3% | $2.74 | $2.74 | $2.19 | 13,848 | |
| $2.665 | -0.405 | -13.2% | $2.94 | $2.94 | $2.359 | 117,602 | |
| $3.07 | -0.10 | -3.2% | $3.06 | $3.24 | $3.06 | 9,704 | |
| $3.17 | +0.11 | +3.6% | $3.08 | $3.261 | $2.87 | 11,863 | |
| $3.06 | -0.43 | -12.3% | $3.56 | $3.60 | $3.05 | 30,844 | |
| $3.49 | +0.01 | +0.3% | $3.774 | $3.784 | $3.365 | 43,216 | |
| $3.48 | -0.18 | -4.9% | $3.66 | $3.66 | $3.28 | 7,424 | |
| $3.66 | +0.08 | +2.2% | $3.614 | $3.85 | $3.614 | 15,607 | |
| $3.58 | -0.24 | -6.3% | $3.82 | $3.898 | $3.561 | 15,850 | |
| $3.82 | -0.25 | -6.1% | $3.95 | $4.07 | $3.79 | 12,891 | |
| $4.07 | +0.04 | +1.0% | $4.03 | $4.33 | $3.94 | 17,784 | |
| $4.03 | +0.095 | +2.4% | $4.06 | $4.54 | $3.96 | 12,245 | |
| $3.935 | -0.115 | -2.8% | $3.97 | $4.01 | $3.82 | 24,230 | |
| $4.05 | -0.38 | -8.6% | $4.37 | $4.37 | $3.827 | 51,913 | |
| $4.43 | -0.35 | -7.3% | $4.71 | $4.743 | $4.00 | 40,386 | |
| $4.78 | -0.32 | -6.3% | $5.04 | $5.54 | $4.355 | 35,864 | |
| $5.10 | -1.85 | -26.6% | $6.91 | $7.15 | $4.925 | 61,785 | |
| $6.95 | -0.45 | -6.1% | $7.18 | $7.18 | $6.733 | 8,674 | |
| $7.40 | 0.00 | 0.0% | $7.20 | $7.40 | $6.925 | 8,879 | |
| $7.40 | +0.22 | +3.1% | $7.35 | $7.40 | $6.80 | 8,761 | |
| $7.18 | +0.56 | +8.5% | $6.70 | $7.41 | $6.70 | 28,550 | |
| $6.62 | +0.27 | +4.3% | $6.42 | $6.85 | $6.40 | 6,385 | |
| $6.35 | -0.37 | -5.5% | $6.99 | $6.99 | $6.35 | 7,377 | |
| $6.72 | +0.23 | +3.5% | $6.35 | $6.95 | $6.30 | 13,680 | |
| $6.49 | -0.54 | -7.7% | $7.04 | $7.50 | $6.02 | 24,763 | |
| $7.03 | +0.13 | +1.9% | $6.43 | $7.29 | $6.055 | 42,311 | |
| $6.90 | -0.06 | -0.9% | $6.80 | $7.46 | $5.60 | 31,299 | |
| $6.96 | +0.32 | +4.8% | $6.92 | $7.00 | $6.60 | 569 | |
| $6.64 | -1.40 | -17.4% | $7.60 | $7.76 | $6.64 | 1,721 | |
| $8.04 | -0.32 | -3.8% | $8.64 | $9.00 | $7.96 | 850 | |
| $8.36 | -1.88 | -18.4% | $10.20 | $10.36 | $7.20 | 2,558 | |
| $10.24 | +2.20 | +27.4% | $8.00 | $10.52 | $7.20 | 10,561 | |
| $8.04 | -0.20 | -2.4% | $9.00 | $9.00 | $8.00 | 211 | |
| $8.24 | -0.16 | -1.9% | $8.36 | $9.00 | $7.80 | 530 | |
| $8.40 | -0.16 | -1.9% | $8.68 | $9.00 | $8.20 | 198 | |
| $8.56 | +0.16 | +1.9% | $9.00 | $9.00 | $8.12 | 418 | |
| $8.40 | -0.40 | -4.5% | $8.80 | $9.00 | $8.40 | 238 | |
| $8.80 | +0.60 | +7.3% | $8.04 | $8.80 | $8.00 | 147 | |
| $8.20 | +0.56 | +7.3% | $8.20 | $8.80 | $7.80 | 510 | |
| $7.64 | +0.12 | +1.6% | $7.80 | $8.40 | $7.40 | 478 | |
| $7.52 | 0.00 | 0.0% | $7.60 | $7.60 | $7.24 | 406 | |
| $7.52 | +0.52 | +7.4% | $7.28 | $7.80 | $7.04 | 321 | |
| $7.00 | -0.96 | -12.1% | $8.00 | $8.00 | $6.96 | 851 |
Splits
1 split · NASDAQ:NRSN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:NRSN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 2, 2026
NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 32 slides
Latest news
NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
Nov 2, 2026
Closed $1.43 (-28.1%) on Nov 2, 2026
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
Oct 29, 2026
Closed $2.13 (-9.7%) on Oct 29, 2026
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
Oct 19, 2026
Closed $2.67 (-13.2%) on Oct 19, 2026
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
Oct 13, 2026
Closed $3.49 (+0.3%) on Oct 13, 2026
NeuroSense Provides Update on Nasdaq Listing Compliance
Oct 2, 2026
Closed $4.03 (+2.4%) on Oct 5, 2026
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Sep 28, 2026
Closed $5.10 (-26.6%) on Sep 28, 2026
NeuroSense Provides Business Update and Progress for the First Half of 2026
Sep 25, 2026
Closed $5.10 (-26.6%) on Sep 28, 2026
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
Sep 10, 2026
Closed $6.64 (-17.4%) on Sep 10, 2026
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
Aug 31, 2026
Closed $8.56 (+1.9%) on Aug 31, 2026
NeuroSense Issues CEO Letter to Shareholders
Aug 13, 2026
Closed $8.88 (-5.5%) on Aug 13, 2026
NeuroSense Therapeutics Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 36 in the last 12 months · 137 in all · newest Nov 2, 2026 · oldest 2021
- Decks
- 18 decks · latest July 2026
Where NeuroSense Therapeutics Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NRSN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:NRSN | BOATS | United States | USD |
| Frankfurt:H1Z | Frankfurt | Germany | EUR |
Valuation
Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.20M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.41
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. · NASDAQ:NRSN | US$2.43M | US$2.20M | n/a | n/a | n/a | n/a | n/a | n/a | 1.41 |
| BioAtla, Inc. · NASDAQ:BCAB | US$2.58M | US$2.01M | n/a | n/a | n/a | n/a | n/a | n/a | -0.34 |
| Invion Ltd. · ASX:IVX | US$2.49M | US$3.12M | n/a | 12.2× | n/a | 0.7× | n/a | 0.3× | n/a |
| GRI Bio, Inc. · NASDAQ:GRI | US$2.45M | −US$6.99M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.89 |
| ValiRx PLC · LSE:VAL | US$2.42M | US$1.15M | n/a | 28.0× | n/a | 0.6× | n/a | 0.0× | n/a |
| BSF Enterprise PLC · LSE:BSFA | US$2.40M | US$2.95M | n/a | 42.7× | n/a | 1.0× | n/a | 0.3× | n/a |
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Mustang Bio, Inc. · NASDAQ:MBIO | US$2.38M | −US$11.89M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.01 |
| Quest PharmaTech Inc. · TSXV:QPT | US$2.36M | US$2.30M | 0.7× | n/a | n/a | 0.1× | n/a | 0.0× | 1.90 |
| HCW Biologics Inc. · NASDAQ:HCWB | US$2.35M | US$8.23M | n/a | 1.2× | n/a | 0.3× | −63.4% | 1.0× | 1.19 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Median of the others | US$2.40M | US$1.58M | 0.7× | 20.1× | 0.4× | −63.4% | 0.1× | 1.01 |
Forecasts
1 strong buy · 2 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 91.75 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.88 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Alon Ben-Noon | CEO & Board Member |
| Or Eisenberg | Chief Financial Officer |
| Shiran Zimri | VP R&D | Country Lead, Canada |
| Hagit Binder | General Manager |
| Niva Russek-Blum | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Mark Leuchtenberger | Chairman of the board |
| Alon Ben-Noon | CEO & Board Member |
| Cary Claiborne | Board Member |
| Christine Pellizzari | Board Member |
| Revital Mandil-Levin | Board Member |
| Roy Golan | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | Jun 30, 2026 | +2.0% |
| Q4 2025 | Mar 25, 2026 | +5.5% |
| Q3 2025 | Nov 26, 2025 | +14.4% |
| Q2 2025 | Aug 1, 2025 | −30.0% |
| Q1 2025 | Apr 7, 2025 · After close | −2.3% |
| Q3 2024 | Dec 18, 2024 · Before open | +4.6% |
| Q2 2024 | Sep 30, 2024 · After close | −3.9% |
| Q1 2024 | Jun 24, 2024 · Before open | −5.8% |
| Q4 2023 | Mar 29, 2024 · Before open | +0.6% |
| Q3 2023 | Nov 28, 2023 · Before open | +6.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 16, 2023 · After close | −3.3% |
| Q1 2023 | Jun 1, 2023 · Before open | +0.6% |
| Q4 2022 | Mar 22, 2023 · Before open | −4.6% |
| Q3 2022 | Dec 1, 2022 · Before open | −1.2% |
| Q2 2022 | Aug 31, 2022 · Before open | −2.0% |
| Q1 2022 | May 31, 2022 · Before open | −5.4% |
| Q4 2021 | Mar 2, 2022 | +3.8% |
| Q3 2021 | Dec 10, 2021 · Before open | −20.5% |
| Quarter to Mar 31, 2021 | Jun 30, 2021 | |
| Quarter to Dec 31, 2020 | Mar 31, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 32 slides | July 2026 |
| Investor Presentation (April 2024) | Investor deck | 42 slides | Apr 10, 2024 |
| Investor Presentation (February 2024) | Investor deck | 40 slides | Feb 22, 2024 |
| Investor Presentation (January 2024) | Investor deck | 33 slides | Jan 9, 2024 |
| Investor Presentation (December 2023) | Investor deck | 33 slides | Dec 21, 2023 |
| Investor Presentation (September 2023) | Investor deck | 25 slides | Sep 12, 2023 |
| Investor Presentation (June 2023) | Investor deck | 34 slides | Jun 8, 2023 |
| Investor Presentation (April 2023) | Investor deck | 33 slides | Apr 20, 2023 |
| Investor Presentation (March 2023) | Investor deck | 27 slides | Mar 20, 2023 |
| Investor Presentation (November 2022) | Investor deck | 34 slides | Nov 29, 2022 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2022) | Investor deck | 36 slides | Nov 3, 2022 |
| Investor Presentation (August 2022) | Investor deck | 30 slides | Aug 9, 2022 |
| Investor Presentation (July 2022) | Investor deck | 31 slides | Jul 5, 2022 |
| Investor Presentation (June 2022) | Investor deck | 29 slides | Jun 7, 2022 |
| Investor Presentation (May 2022) | Investor deck | 29 slides | May 2, 2022 |
| Investor Presentation (March 2022) | Investor deck | 28 slides | Mar 15, 2022 |
| Investor Presentation (February 2022) | Investor deck | 28 slides | Feb 15, 2022 |
| IPO Roadshow (November 2021) | IPO roadshow | 28 slides | Nov 10, 2021 |
Financings
| Raise | Date |
|---|---|
| Private placement of ordinary shares Announced: US$600,000 · US$0.8 a share Buyers: Alon Ben-Noon ($200,000); Or Eisenberg ($200,000) Insiders: CEO Alon Ben-Noon and CFO Or Eisenberg each committed $200,000 Use of proceeds: General corporate purposes ahead of upcoming clinical and regulatory milestones | Apr 28, 2026 |
| Private placement of ordinary shares Announced: US$500,000 · US$1.5 a share Use of proceeds: General corporate purposes and working capital | Sep 4, 2025 |
| Private placement of ordinary shares (or ordinary share equivalents) and warrants Closed: US$5M raised · US$1.25 a share · Warrants at US$1.25 for 60 months Buyers: Alon Ben-Noon Insiders: Chief Executive Officer Alon Ben-Noon entered into the definitive agreement to purchase in the private placement alongside a single investor Use of proceeds: General corporate and working capital purposes | Dec 18, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$6.00 a unit on Dec 8, 2021.
- Price
- US$6.00 a unit
- Units offered
- 2,000,000 units
- Offering size
- US$12 million
- Underwriters' option
- Up to 300,000 more units
- Listing
- NRSN on the Nasdaq Capital Market
- Underwriter
- Sole Book-Running Manager Maxim Group LLC
- Units delivered
- On or about Dec 13, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 10, 2021 |
| Filed publicly | Oct 18, 2021 |
| Amended 4 times | Newest Dec 6, 2021 |
| Shares registered with an exchange | Nov 18, 2021 |
| Declared effective by the SEC | Dec 8, 2021 |
| Final prospectus, with the price | Dec 10, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 10, 2021 |
| EFFECT · Notice that a registration is effective | Dec 8, 2021 |
| CERT · Exchange's certificate of listing | Dec 8, 2021 |
| CORRESP · Letter to the SEC | Dec 6, 2021 |
| CORRESP · Letter to the SEC | Dec 6, 2021 |
| FWP · Free writing prospectus | Dec 6, 2021 |
| F-1/A · Registration statement, amended | Dec 6, 2021 |
| CORRESP · Letter to the SEC | Nov 19, 2021 |
| F-1/A · Registration statement, amended | Nov 19, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 18, 2021 |
All 25 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Nov 16, 2021 |
| FWP · Free writing prospectus | Nov 10, 2021 |
| F-1/A · Registration statement, amended | Nov 10, 2021 |
| CORRESP · Letter to the SEC | Nov 4, 2021 |
| F-1/A · Registration statement, amended | Nov 1, 2021 |
| CORRESP · Letter to the SEC | Oct 18, 2021 |
| F-1 · Registration statement | Oct 18, 2021 |
| UPLOAD · Letter from the SEC | Oct 15, 2021 |
| DRS/A · Draft registration statement, amended | Oct 7, 2021 |
| DRSLTR · Letter to the SEC with a draft | Oct 6, 2021 |
| UPLOAD · Letter from the SEC | Oct 1, 2021 |
| DRSLTR · Letter to the SEC with a draft | Sep 21, 2021 |
| DRS/A · Draft registration statement, amended | Sep 21, 2021 |
| UPLOAD · Letter from the SEC | Sep 3, 2021 |
| DRS · Draft registration statement | Aug 10, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 10, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 22.0K | 97.0K | 89.0K | 3.00K | 3.00K | ||
| Gross profit | -22.0K | -97.0K | -89.0K | -3.00K | -3.00K | ||
| Research and development | 6.23M | 5.70M | 7.27M | 5.59M | 1.39M | 2.50M | 898.0K |
| Selling, general and administrative | 4.86M | 4.20M | 4.78M | 7.14M | 2.50M | 393.0K | 337.0K |
| Operating income | -11.1M | -9.90M | -12.0M | -10.6M | -2.98M | -2.89M | -1.24M |
| Depreciation and amortization | 16.0K | 22.0K | 21.0K | 12.0K | 3.00K | 3.00K | 1.24M |
| EBITDA | -11.1M | -9.88M | -12.0M | -10.5M | -2.98M | -2.88M | 0 |
| Interest expense | 311.0K | 550.0K | 15.0K | 1.15M | 1.00K | 5.00K | |
| Income before tax | -11.1M | -10.2M | -10.1M | -12.3M | -4.04M | -2.83M | -1.22M |
| Income tax | -1 | -1.14M | -1.55M | 1.00K | 5.00K | ||
| Net income | -11.1M | -10.2M | -10.1M | -10.5M | -3.22M | -2.83M | -1.23M |
| Earnings per share, basic | -0.44 | -0.54 | -0.74 | -0.91 | -0.52 | -10.25 | -4.50 |
| Earnings per share, diluted | -0.44 | -0.54 | -0.74 | -0.91 | -0.52 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 166.0K | 3.38M | 2.64M | 3.54M | 11.1M | 699.0K | 895.0K |
| Short-term investments | 0 | 3.55M | 0 | ||||
| Receivables | 33.0K | 164.0K | 166.0K | 131.0K | 178.0K | 30.0K | 18.0K |
| Inventory | -3.68M | -178.0K | -67 | -18 | |||
| Current assets | 778.0K | 4.40M | 2.92M | 7.38M | 11.4M | 729.0K | 913.0K |
| Property, plant and equipment | 58.0K | 66.0K | 85.0K | 77.0K | 19.0K | 13.0K | 7.00K |
| Total assets | 1.03M | 4.58M | 3.19M | 7.72M | 11.4M | 779.0K | 955.0K |
| Accounts payable | 799.0K | 1.16M | 1.46M | 498.0K | 39.0K | 55.0K | 23.0K |
| Current liabilities | 2.52M | 1.99M | 3.46M | 1.73M | 597.0K | 120.0K | 37.0K |
| Total debt | 170.0K | 73.0K | 142.0K | 211.0K | 1.83M | ||
| Total liabilities | 2.59M | 1.99M | 4.94M | 1.87M | 2.42M | 120.0K | 37.0K |
| Shareholders' equity | -1.56M | 2.58M | -1.76M | 5.84M | 10.8M | 659.0K | 918.0K |
| Shares outstanding | 32.6M | 23.2M | 15.4M | 11.8M | 23.2M | 275.9K | 272.7K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -7.67M | -10.1M | -8.35M | -7.62M | -1.54M | -695.0K | -582.0K |
| Capital spending | -8.00K | -3.00K | -29.0K | -70.0K | -17.0K | -9.00K | -7.00K |
| Free cash flow | -7.68M | -10.1M | -8.38M | -7.69M | -1.56M | -704.0K | -589.0K |
| Cash from investing | -8.00K | 1.00K | 3.47M | -3.59M | -17.0K | -9.00K | -26.0K |
| Cash from financing | 4.43M | 10.9M | 3.98M | 3.77M | 11.9M | 508.0K | 1.42M |
| Change in cash | -3.21M | 738.0K | -903.0K | -7.52M | 10.4M | -196.0K | 809.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 18, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 26, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 13, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 25, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 27, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 13, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 315 filings. Open Filings
Cap table
Built by 6ix from NeuroSense Therapeutics Ltd.’s releases · as of Apr 28, 2026
- Common shares
- 1,896,902
- Fully diluted
- 1,896,902
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,896,902 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.25 · expire about Dec 2029 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,896,902 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cary Claiborne Other companies: Adial Pharmaceuticals, Inc (Chief Executive Officer, Director · Since at least Apr 7, 2026); Azora Therapeutics, Inc. (Chief Executive Officer, Director · Since at least May 29, 2025) | Board Member · Since at least Mar 18, 2026 |
| Roy Golan Other companies: MySize, Inc. (Director · Since at least Mar 6, 2025); Ayala Pharmaceuticals Inc (Chief Financial Officer · Oct 18, 2023 – Oct 18, 2023 · Past) | Board Member · Since at least Mar 18, 2026 |
| Or Eisenberg Other companies: Big Digital Energy, Inc. (CFO and Secretary · Nov 16, 2017 – Mar 9, 2021 · Past) | Chief Financial Officer · Since at least Mar 18, 2026 |
| Alon Ben-Noon | CEO & Board Member · Since at least Jun 17, 2026 |
| Christine Pellizzari | Board Member · Since at least Nov 5, 2026 |
| Ferenc Tracik | Chief Medical Officer · Since at least Mar 18, 2026 |
| Hagit Binder | General Manager · Since at least Nov 21, 2024 |
| Mark Leuchtenberger | Chairman of the board · Since at least Nov 5, 2026 |
| Niva Russek-Blum | Chief Technology Officer · Since at least Mar 18, 2026 |
| Revital Mandil-Levin | Board Member · Since at least Mar 18, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Shiran Zimri | VP R&D | Country Lead, Canada · Since at least Oct 29, 2026 |
Log in to ask 6ix AI your own questions about NeuroSense Therapeutics Ltd.